Ketanserin and red blood cell sodium content in hypertension.
The sodium content of erythrocytes from patients with essential hypertension is increased. In a double-blind, placebo-controlled study, a 5-day treatment with ketanserin, a serotonergic antagonist lowered significantly the sodium content of the red blood cells (RBC). Ouabain induces an increase of sodium content of the RBC, which is paralleled by a decrease in RBC deformability. The ouabain-dependent fraction of RBC deformability is significantly reduced after a single oral dose of ketanserin. In vitro, serotonin (5-HT) decreases RBC deformability; this effect could be antagonized by ketanserin. These data might suggest a regulating role of 5-HT in transmembrane ion fluxes.
De Cree
J
J
Leempoels
J
J
Demoen
B
B
Verhaegen
H
H
D000328:Adult; D000368:Aged; D004907:Erythrocyte Deformability / Q000187:drug effects; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000097:blood*; D007650:Ketanserin; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D010042:Ouabain / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*; D012964:Sodium / Q000097:blood*
D010880:Piperidines; D012702:Serotonin Antagonists; D012701:Serotonin; D010042:Ouabain; D007650:Ketanserin; D012964:Sodium